Therefore, the present study aimed to evaluate the modulatory effect of regorafenib as a multikinase inhibitor on P2X7R expression and the P2X7/hypoxia/angiogenesis/autophagy signaling axis in the MCF7 breast cancer cell line. This evidence concerns the gene P2RX7 and breast carcinoma.